Q-omics provides the consensus-scored C4orf36 profile across patient tissues and cancer cell-line models. C4orf36 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C4orf36 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, C4orf36 RNA expression shows 18,745 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where C4orf36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4orf36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4orf36 survival associations across molecular data types. C4orf36 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4orf36 RNA expression–survival associations across cancer types. High C4orf36 expression shows unfavorable associations in LGG, PAAD and BLCA, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C4orf36 RNA expression.
This table summarizes C4orf36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C4orf36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4orf36 shows lower tumor expression in THCA, BLCA, KIRC, BRCA and KIRP and higher tumor expression in CHOL. The THCA box plot shows higher C4orf36 RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with C4orf36 in patient tissues and cancer cell lines. In patient samples, C4orf36 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C4orf36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
